PrIMAVeRa Consortium holds Annual Meeting in Madrid

13 November 2025

Consortium partners of the PrIMAVeRa project met in Madrid from 06-07 November for the project’s fourth annual meeting.  Held in hybrid format, the meeting allowed virtual attendees to engage in discussions with the face-to-face participants on the campus of the Insituto de Salud Carlos III.  The event provided the opportunity for more than 40 individuals representing the project’s 17 partner organisations to meet, align, and advance progress towards project aims.

PrIMAVeRa consortium members at the 4th Annual Meeting

Principal investigators presented on the past year’s progress made towards modelling the impact of vaccines and monoclonal antibodies on antimicrobial resistance, as well as the cost-effectiveness of these interventions, across three target pathogens: Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. A generic, more flexible model is also under development.  Plans for sustainability of project outputs were also presented and discussed.  Breakout sessions were organised for smaller teams to tackle issues pertaining to the individual pathogen models, and conclusions were then presented to the larger group for discussion.

Partners benefitted from two keynote addresses:

• Bridging the Gap Between Unmet Need and Market Access for Bacterial Vaccines, given by Dr. Juan-José Infante, CEO (Vaxdyn S.L.)

• Building the Future of AMR Genomic Surveillance: The RedLabRA Experience, given by María Peréz Vásquez (ISCIII)

The meeting focused on aligning next steps toward the finalisation of PrIMAVeRa’s modelling, analytical, and dissemination workstreams. Participants agreed on several key priorities to complete the project:

• Finalisation of the Generic Model: The consortium will finalise the generic modelling framework and include vaccination scenarios that reflect realistic opportunities for vaccine development and introduction in Europe.

• Refinement of Individual Models: Partners will refine individual disease models based on consensus discussions

• Data Completion and Exchange: Final data collection activities will be completed, including structured data exchange between PrIMAVeRa and IHME to enable harmonised analyses.

• Integration of Cost-Effectiveness Analyses: Economic modelling will be expanded to assess the cost-effectiveness of vaccines and monoclonal antibodies in preventing drug-resistant infections.

• Dashboard Refinement: The dashboard will be optimised to ensure that results are clearly visualised, user-friendly, and aligned with the needs of the intended end users.

• Communication and Dissemination: A targeted communication plan will be developed to ensure project outputs reach and inform relevant policy, research, and industry stakeholders.

Going forward, the Consortium will focus on finalising the generic model and several individual models. Data acquisition is still required, and this process is ongoing. The Consortium will also map out the project assets, and work on the sustainability plan is in progress.

Members of the project’s Scientific Advisory Committee were also present virtually and in-person to provide valuable feedback.  The committee appreciated the strong progress toward deliverables and publications and encouraged maintaining focus on achievable outputs within the remaining year. They stressed the importance of clearly planning for sustainability and external user engagement. The experts welcomed the project’s links with COMBINE and its collaborative approach. They emphasised the need for clear communication and dissemination plans for the dashboard, ensuring the right stakeholders are reached. Finally, they advised aligning models and analyses closely with real-world clinical pathways, antibiotic use, and decision-making processes to maximise relevance and impact.

The annual meeting served as a catalyst towards maintaining momentum leading into the project’s final year.

---

This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and

innovation programme and EFPIA.  www.imi.europa.eu

This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.